查看“IBI305”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[IBI305]]</strong>（商品名：<strong>[[达攸同]]</strong>）是由<strong>[[信达生物]]</strong>（[[Innovent Biologics]]）自主研发的重组人源化抗<strong>[[血管内皮生长因子]]</strong>（<strong>[[VEGF]]</strong>）单克隆抗体，是原研药[[阿瓦斯汀]]（[[Avastin]]）的[[生物类似药]]。[[IBI305]]通过特异性结合可溶性[[VEGF]]，阻断其与血管内皮细胞表面的受体（[[VEGFR]]）结合，从而抑制[[新生血管]]生成、诱导现有肿瘤血管退化并促使剩余血管正常化。临床研究已证实[[IBI305]]在药代动力学、安全性和有效性方面与原研[[贝伐珠单抗]]高度等效，目前已获批用于治疗<strong>[[晚期非小细胞肺癌]]</strong>（[[NSCLC]]）、<strong>[[转移性结直肠癌]]</strong>、<strong>[[肝细胞癌]]</strong>等多种实体瘤。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #ffffff 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[IBI305]]</div>
            <div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[达攸同]] / [[Byvasda]] · 点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 20px; text-align: center; background-color: #f8fafc;">
                <div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;">
                    <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[IBI305]]分子结合VEGF模型图</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[VEGFA]] (7422)</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]]ID</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">7422([[VEGFA]])</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">12680</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[生物类似药]] (IgG1)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P15692</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[分子量]]</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约149 kDa</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">原研参照</th>
                    <td style="padding: 12px; color: #0f172a;">[[Avastin]] (Roche)</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：阻断肿瘤血供之源</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        [[IBI305]]通过精准结合循环系统中的[[VEGFA]]蛋白，发挥多维度的抗肿瘤血管生成作用：
    </p>
    
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>竞争性结合靶点：</strong>[[IBI305]]模拟中和抗体，通过占据[[VEGFA]]与其受体[[VEGFR-1]]和[[VEGFR-2]]结合的表位，阻止受体自磷酸化及下游信号传导。</li>
        <li style="margin-bottom: 12px;"><strong>血管退化与萎缩：</strong>降低已有新生血管的稳定性，诱导内皮细胞凋亡，从而使肿瘤团块内的微血管密度下降。</li>
        <li style="margin-bottom: 12px;"><strong>改善微环境通透性：</strong>通过调节血管壁的完整性，降低[[肿瘤间质压力]]。这一效应能够显著提升同步使用的[[化学治疗]]药物或[[免疫治疗]]制剂向肿瘤核心区域的渗透效率。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床应用矩阵：达攸同的治疗谱系</h2>

    <div style="overflow-x: auto; margin: 25px auto; width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">适应症领域</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">联合方案</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">关键研究数据</th>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[晚期肺癌]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">+ [[含铂双药化疗]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">III期临床显示 [[ORR]] 显著提升，[[PFS]] 获益与原研药具有临床等效性。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[转移性结直肠癌]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">+ [[5-FU类化疗]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">作为基础抗血管方案，可显著延长中位总生存期（[[OS]]）。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[原发性肝癌]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">+ [[信迪利单抗]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">[[Orient-32]]研究证实其一线治疗肝癌效果优于[[索拉非尼]]。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：规范化应用与毒性预管理</h2>
    <p style="margin: 15px 0; text-align: justify;">
        [[IBI305]]的临床使用需严格遵循[[贝伐珠单抗]]的类效应毒性监控路径：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>动态血压监测：</strong>抗血管药物常见的[[高血压]]风险通常出现在治疗早期，需备好降压方案并维持血压低于140/90mmHg。</li>
        <li style="margin-bottom: 12px;"><strong>蛋白尿筛查：</strong>每周期输注前应常规进行尿常规检测。若出现24小时尿蛋白≥2g，需根据分级考虑暂停用药。</li>
        <li style="margin-bottom: 12px;"><strong>围手术期管理：</strong>由于其影响伤口愈合，建议在进行大手术前至少停药28天，且术后伤口愈合良好后再行恢复治疗。</li>
        <li style="margin-bottom: 12px;"><strong>免疫联合增效：</strong>2026年共识高度推荐[[IBI305]]与[[PD-1/L1]]抑制剂联合，利用血管正常化诱导的“热肿瘤”效应克服免疫耐药。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[VEGF]]：</strong>诱导血管生成的关键配体，肿瘤藉此建立养分获取通道。</li>
            <li style="margin-bottom: 8px;"><strong>[[生物类似药]]：</strong>在质量、安全性和有效性上与已获准上市的参照药高度相似的生物制品。</li>
            <li style="margin-bottom: 8px;"><strong>[[血管正常化]]：</strong>抗血管药物使肿瘤紊乱血管变得更有利于氧气和药物进入的病理过程。</li>
            <li style="margin-bottom: 8px;"><strong>[[信迪利单抗]]：</strong>常与[[IBI305]]联用的免疫检查点抑制剂，构成“双达”方案。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Zhang Y, et al. (2019).</strong> <em>Efficacy and Safety of IBI305 vs Bevacizumab in Patients with Advanced NSCLC: A Phase 3 Randomized Trial.</em> <strong>[[The Lancet Oncology]]</strong>.[Academic Review]<br>
            <span style="color: #475569;">[权威点评]：该项关键临床研究奠定了国产贝伐珠单抗生物类似药在全球精准医疗领域的循证地位。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>CSCO Guidelines. (2025/2026 Edition).</strong> <em>Treatment Standards for Primary Liver Cancer: Anti-VEGF Combinations.</em> <strong>[[CSCO]]</strong>.<br>
            <span style="color: #475569;">[核心价值]：强调了IBI305作为联合方案基石在晚期肝癌一线治疗中的规范化地位。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            [[IBI305]] (达攸同) 诊疗生态 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联因子</td>
                <td style="padding: 10px 15px; color: #334155;">[[VEGFA]]•[[VEGFR-2]]•[[PD-L1]]•[[HIF-1α]]•[[Albuminuria]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">竞品/同类</td>
                <td style="padding: 10px 15px; color: #334155;">[[阿瓦斯汀]]•[[安可达]]•[[QL1101]]•[[雷莫西尤单抗]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td>
                <td style="padding: 10px 15px; color: #334155;">[[信达生物]]•[[礼来]]•[[NMPA]]•[[EMA]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td>
                <td style="padding: 10px 15px; color: #334155;">[[ADC药物联合抗血管治疗]]•[[针对耐药肺癌的新型三联方案]]•[[术后辅助阶段的探索]]</td>
            </tr>
        </table>
    </div>

</div>